| Authors: |
Robert M; Institut de Cancérologie de l'Ouest, Saint-Herblain, ARPEGO Network, France., Kotecki N; Institut Jules Bordet, Brussels, Belgium., Gomez-Roca C; IUCT-Oncopole Claudius Régaud, Toulouse, France., Massard C; Centre Eugène Marquis, Rennes, France., Postel-Vinay S; Institut Gustave Roussy, Villejuif, France., Raimbourg J; Institut de Cancérologie de l'Ouest, Saint-Herblain, ARPEGO Network, France., Brandao M; Institut Jules Bordet, Brussels, Belgium., Korakis I; IUCT-Oncopole Claudius Régaud, Toulouse, France., Rouge TM; Centre Eugène Marquis, Rennes, France., Comis S; OSE Immunotherapeutics, Nantes, France., Imadalou K; OSE Immunotherapeutics, Nantes, France., Chevalier C; OSE Immunotherapeutics, Nantes, France., Cordonnier L; OSE Immunotherapeutics, Nantes, France., Josse C; Exystat, Malakoff, France., Teppaz G; OSE Immunotherapeutics, Nantes, France., Seité M; OSE Immunotherapeutics, Nantes, France., Durand J; OSE Immunotherapeutics, Nantes, France., Thepenier V; OSE Immunotherapeutics, Nantes, France., Mary C; OSE Immunotherapeutics, Nantes, France., Gauttier V; OSE Immunotherapeutics, Nantes, France., Derame M; OSE Immunotherapeutics, Nantes, France., Morello A; OSE Immunotherapeutics, Nantes, France., Poirier N; OSE Immunotherapeutics, Nantes, France., Cassier PA; Centre Léon Bérard, Lyon, France. Electronic address: philippe.cassier@lyon.unicancer.fr. |
